^
Association details:
| Biomarker: | Chr amplification(1)(q21) |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | thalidomide (TNF inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Lenalidomide Versus Thalidomide or Bortezomib As Maintenance Regimens for Non-Transplant Patients with Multiple Myeloma: Multi-Center Real World Experience in China
Published date:
11/04/2021
Excerpt:
...we conducted this retrospective real-world study on efficacy and safety of the mainstream maintenance regimens in non-transplant NDMM patients-thalidomide (T-MT), lenalidomide (L-MT) and bortezomib (B-MT)....Patients with 1q21+ on T-MT had shorter median PFS compared to those without (12.2m vs 21.0m, p=0.08), as well as impaired median OS (53.1m vs 81.0m, p= 0.004), despite various second line therapies.
DOI:
https://doi.org/10.1182/blood-2021-149502
Source:
Title:
LENALIDOMIDE VERSUS THALIDOMIDE OR BORTEZOMIB AS MAINTENANCE REGIMEN FOR NON-TRANSPLANT PATIENTS WITH MULTIPLE MYELOMA: MULTI-CENTER REAL WORLD EXPERIENCES IN CHINA
Published date:
05/12/2021
Excerpt:
We conducted this multi-centered retrospective real-world study on efficacy and safety of the mainstream maintenance regimens, thalidomide (T-MT)...Patients with 1q21+ on T-MT had shorter median PFS compared to those without (16.1m vs 22.5m, p=0.14), so did impaired median OS (52.3m vs 96.5m, p= 0.003)....Only a few patients with 17p- in T-MT and B-MT, yet presented remarkably inferior PFS (6.7m vs 22.5m, p=0.007) and OS (39.6m vs 79.5m, p=0.02) with T-MT.
